ClinicalTrials.gg
TerminatedNCT00974740Updated Jun 19, 2017

DIATOR-Diabetes Intervention With Atorvastatin

A Phase 1 interventional study of Atorvastatin and atorvastatin matching placebo in Type 1 Diabetes, sponsored by Profil Institut für Stoffwechselforschung GmbH. Terminated at 12 sites in Germany. Open to participants aged 18 Years to 39 Years. Per ClinicalTrials.gov, last updated 2017-06-19.

Sponsored by Profil Institut für Stoffwechselforschung GmbH · Phase 1, Interventional, and Treatment

Why this study was terminated
for lack of recruitment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years to 39 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 294 studies in Diabetes Mellitus, Type 1 with a site in Germany — 22 open to participants now, 31 under way, 6 of them phase 3. Diabetes Mellitus, Type 1 · Germany.

Enrollment
128th of 260
63 · median 61
Started
2004
with 6 others
Phase 1
105 of 294
4 open now
Registered
38th of 294
by date

Among the 294 studies in Diabetes Mellitus, Type 1 with a site in Germany, this one is the 128th largest by enrollment of the 260 interventional ones that give a count, is one of 7 that started in 2004, is one of 105 in phase 1, and was the 38th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

22 of the 294 studies in Diabetes Mellitus, Type 1 with a site in Germany are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 39 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 294 studies in Diabetes Mellitus, Type 1 with a site in Germany, or all of them as a file.
02

Study summary

Clinical studies have shown that immunomodulators (like Anti-CD3 antibodies) have effects on beta-cell-preservation. The lipid-lowering agent atorvastatin is also a potent immunomodulator. In this study the effects of 80 mg atorvastatin per day on preservation of beta-cell function in recent onset type 1 diabetes were studied, as determined by stimulated C-peptide levels.

Read the detailed description

The objectives of this study were as follows:

  • To assess the effect of atorvastatin on pancreatic beta-cell function as measured by C-peptide after a liquid mixed meal stimulation in patients with newly diagnosed type 1 diabetes,
  • To assess the effect on metabolic control as measured by HbA1c and insulin requirements,
  • To assess safety and tolerability of atorvastatin in subjects with newly diagnosed type 1 diabetes,
  • To assess the effect on risk factors of diabetic complications as indicated by changes in lipids and CRP, and
  • To assess the effect on systemic immune abnormalities as measured by effects on beta-cell autoantibodies, blood cytokines and chemokines on protein and transcriptional level.

Study duration: 18 months

03

Conditions studied

  • Type 1 Diabetes

Keywords

  • type 1 diabetes
04

Who can participate

Ages eligible
18 Years to 39 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Insulin treated patients with a newly diagnosed type 1 diabetes mellitus as defined by the ADA criteria at least two weeks but not later than 3 months after start of insulin treatment
  • Age 18 to 39 years, inclusive
  • Male patient or female patient using adequate methods
  • Tested positive for at least one of the three islet autoantibodies GAD65, IA2 or ICA

Exclusion criteria

Exclusion Criteria:

  • History of a
  • Presence of a hepatic or renal disease, as indicated, but not limited to a serum creatinine elevated more than ten percent above the , elevation of or ALT more than 3 times the upper limit of normal
  • Any other acute or chronic condition that may affect the patient's response to treatment or might be associated with an increased risk for the patient to participate, as judged by the investigator
  • Current use of anti-inflammatory or immunomodulatory drugs, antihypertensive, lipid-lowering, or antidiabetic drugs other than insulin
  • Pregnant or nursing women or women intending to become pregnant
  • Known or suspected allergy to atorvastatin or any component of thr trial product
  • Known myopathy, myalgia or myositis with a serum-CPK above 3 times the upper limit of normal
  • Patients who had a severe blood loss (>= 400 mL, e.g. blood donation) within 2 months prior to visit 2
  • Any significant laboratory abnormality
  • A serum LDL-cholesterol above 150 mg/dL at time of screening
  • Unwillingness to comply with study procedures
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
63 participants (actual)

Study arms

  • Placebo comparator
    atorvastatin matching placebo

    atorvastatin matching placebo

    Drug: atorvastatin matching placebo

  • Experimental
    atorvastatin

    40 mg atorvastatin for 4 weeks (run-in period), then 80 mg atorvastatin, total treatment period was 18 months

    Drug: Atorvastatin

Interventions

  • atorvastatin 40 mg (tablet for oral intake) once daily in the evening for 4 weeks, thereafter 80 mg for the remaining treatment period (total treatment period 18 months)

    Also known as: Sortis

  • Drugatorvastatin matching placebo

    atorvastatin matching placebo tablets once daily in the evening, corresponding to 40 mg atorvastatin for the first 4 weeks (run-in period), and corresponding to 80 mg atorvastatin thereafter (total treatment period 18 months)

06

What researchers measure

Primary outcomes

  1. C-peptide after a liquid mixed meal stimulation

    Time frame: at randomization, after 12 months, and after 18 months of treatment

Secondary outcomes

  1. HbA1c

    Time frame: at randomization, after 6, 12, and 18 months of treatment

  2. insulin dose

    Time frame: at randomization, and after 3, 6, 12, and 18 months of treatment

  3. adverse events

    Time frame: at randomization, and after 3, 6, 12, and 18 months of treatment

  4. serum lipids

    Time frame: at randomization, and after 3, 6, 12, and 18 months of treatment

  5. plasma CRP

    Time frame: at randomization, and after 3, 12, and 18 months of treatment

07

Study locations

12 sites
  • Diabetes-Zentrum Mergentheim
    Bad Mergentheim, 97980, Germany
  • Gemeinschaftskrankenhaus Havelhöhe
    Berlin, 14089, Germany
  • Helios Klinikum Emil von Behring
    Berlin, 14165, Germany
  • Praxis Dr. Friedhelm Schmitten
    Bestwig-Ramsbeck, 59909, Germany
  • DDZ Deutsches Diabetes Zentrum
    Düsseldorf, 40221, Germany
  • St. Josefs Krankenhaus
    Heidelberg, 69115, Germany
  • St. Antonius Krankenhaus, Med. Klinik
    Köln, 50968, Germany
  • Praxisklinik Leipzig
    Leipzig, 04103, Germany
  • Praxis Dr. Gerhard Willms
    Leverkusen, 51373, Germany
  • Praxis Dr. Heinz-Georg Ley
    Marl, 45770, Germany
  • Diabetologische Schwerpunktpraxis, Angiologie
    Münster, 48145, Germany
  • Praxis Dr. Werner Stürmer
    Würzburg, 97070, Germany
08

References and documents

Publications

  • Kolb H, Luckemeyer K, Heise T, Herder C, Schloot NC, Koenig W, Heinemann L, Martin S; DIATOR Study Group. The systemic immune network in recent onset type 1 diabetes: central role of interleukin-1 receptor antagonist (DIATOR Trial). PLoS One. 2013 Aug 26;8(8):e72440. doi: 10.1371/journal.pone.0072440. eCollection 2013. PubMed 23991111 ↗
  • Strom A, Kolb H, Martin S, Herder C, Simon MC, Koenig W, Heise T, Heinemann L, Roden M, Schloot NC; DIATOR Study Group. Improved preservation of residual beta cell function by atorvastatin in patients with recent onset type 1 diabetes and high CRP levels (DIATOR trial). PLoS One. 2012;7(3):e33108. doi: 10.1371/journal.pone.0033108. Epub 2012 Mar 20. PubMed 22448235 ↗
  • Martin S, Herder C, Schloot NC, Koenig W, Heise T, Heinemann L, Kolb H; DIATOR Study Group. Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the Randomized DIATOR Trial. PLoS One. 2011 Mar 11;6(3):e17554. doi: 10.1371/journal.pone.0017554. PubMed 21412424 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2004, a primary completion of Jan 2008 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2009
First posted
Sep 10, 2009
Start
Mar 2004
Primary completionActual
Jan 2008
CompletionActual
Mar 2009
Last update
Jun 19, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 19, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00974740
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Sep 10, 2009
Start date
Mar 2004
Primary completion
Jan 2008
Completion
Mar 2009
Last update
Jun 19, 2017

Study contacts

Stefan Martin, MD
principal investigator · DDZ Deutsches Diabetes Zentrum, Düsseldorf, Germany

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion